Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease
- PMID: 33502736
- DOI: 10.1007/s12035-021-02295-z
Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting cognitive function. A number of allelic genes from HLA complex have shown variable associations with AD in different populations. In this study, we investigated the association of DQB1*06:00/x, DRB1*04:00/x, DRB1*15:00/x, and B*07:00/x genotypes with AD and their relevance to the efficacy of rivastigmine treatment in the Iranian population. Our findings suggest that DQB1*06:00/x genotype offers strong protection against AD (P = 0.0074), while B*07:00/x genotype imposes a significant susceptibility for sporadic Alzheimer's disease (SAD) (P = 0.009). Interestingly, B*07:00/x genotype does not show any apparent associations with familial Alzheimer's disease (FAD). Our studies also suggest a pharmacogenetic relationship between drug treatment and presence of a particular genotype in the Iranian LOAD patient population. The Clinical Dementia Rating analysis showed that LOAD patients carrying DRB1*04:00/x genotype tend to display a downward trend in the disease severity and symptoms after 2-year follow-up with rivastigmine treatment. Moreover, in our total patient population, the carriers of DQB1*06:00/x and B*07:00/x alleles have better and worse responses to rivastigmine respectively. We also measured the clinical relevance of the testing for these genotypes employing prevalence-corrected positive predictive value (PcPPV) formula. The PcPPV of testing for DQB1*06:00/x in the Iranian LOAD patients was 1.17% which means that people carrying this genotype have half of the probability of the absolute risk for developing LOAD, whereas the PcPPV of testing for B*07:00/x was 4.45% for SAD, which can be interpreted as a doubling chance for developing LOAD among the Iranian population carrying this genotype. These results also suggest that DQβ1 peptide containing positively charged AAs histidine30 and arginine55 and HLA class I β chain containing negatively charges aspartic acid114 and glutamic acid45,152 in their binding groove plays important roles in protection against and susceptibility for LOAD respectively.
Keywords: Alzheimer; HLA genes; PCR; Pharmacogenetic; Rivastigmine.
Similar articles
-
Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.Mol Neurobiol. 2016 Sep;53(7):4521-8. doi: 10.1007/s12035-015-9387-8. Epub 2015 Aug 21. Mol Neurobiol. 2016. PMID: 26289409
-
Drug Response of Iranian Alzheimer's Patients to Rivastigmine Concerning Their Genotype for VDR rs11568820 and MTHFR C677T Variants: A Pharmacogenetic and Association Study.J Mol Neurosci. 2024 Aug 7;74(3):75. doi: 10.1007/s12031-024-02253-z. J Mol Neurosci. 2024. PMID: 39112893
-
Contribution of HLA class II genes, DRB4*01:01, DRB1*07:01, and DQB1*03:03:2 to clinical features of Vitiligo disease in Iranian population.Mol Biol Rep. 2022 Jan;49(1):171-178. doi: 10.1007/s11033-021-06855-3. Epub 2021 Oct 22. Mol Biol Rep. 2022. PMID: 34686989
-
Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.Methods Find Exp Clin Pharmacol. 2007 Jul;29 Suppl A:1-91. Methods Find Exp Clin Pharmacol. 2007. PMID: 17957277 Review.
-
Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could BCHE Genotyping Be Helpful in Alzheimer's Therapy?Biomolecules. 2019 Oct 9;9(10):592. doi: 10.3390/biom9100592. Biomolecules. 2019. PMID: 31601022 Free PMC article. Review.
Cited by
-
Empirical Study of Large-Scale HLA Simulation of Parallel Region-Matching Knowledge Recognition Algorithm Based on Region Matching.Comput Intell Neurosci. 2022 Apr 11;2022:1514396. doi: 10.1155/2022/1514396. eCollection 2022. Comput Intell Neurosci. 2022. PMID: 35449745 Free PMC article.
-
The HLA-DRB1*09:01-DQB1*03:03 haplotype is associated with the risk for late-onset Alzheimer's disease in APOE 4-negative Japanese adults.NPJ Aging. 2024 Jan 2;10(1):3. doi: 10.1038/s41514-023-00131-3. NPJ Aging. 2024. PMID: 38167405 Free PMC article.
References
-
- Steele NZR, Carr JS, Bonham LW, Geier EG, Damotte V, Miller ZA, Desikan RS, Boehme KL, Mukherjee S, Crane PK, Kauwe JSK, Kramer JH, Miller BL, Coppola G, Hollenbach JA, Huang Y, Yokoyama JS (2017) Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: a case– control study. PLoS Med 14(3):e1002272. https://doi.org/10.1371/journal.pmed.1002272 - DOI - PubMed - PMC
-
- Candore G, Balistreri CR, Colonna-Romano G, Lio D, Caruso C (2004) Major histocompatibility complex and sporadic Alzheimer’s disease: a critical reappraisal. Exp Gerontol 39(4):645–652 - PubMed
-
- Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR et al (1991) Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. Ann Neurol 30(3):381–390 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials